72nd OREGON LEGISLATIVE ASSEMBLY--2003 Regular Session
 
 
                            Enrolled
 
                         House Bill 2558
 
Sponsored by Representative KRUSE
 
 
                     CHAPTER ................
 
 
                             AN ACT
 
 
Relating to Drug Use Review Board; amending ORS 414.360 and
  414.370.
 
Be It Enacted by the People of the State of Oregon:
 
  SECTION 1. ORS 414.360 is amended to read:
  414.360.  { + (1) + } The Drug Use Review Board shall advise
the Department of Human Services on:
    { - (1) - }   { + (a) + } Adoption of rules to implement ORS
414.350 to 414.415 in accordance with the provisions of ORS
chapter 183.
    { - (2) - }   { + (b) + } Implementation of the medical
assistance program retrospective and prospective programs as
described in ORS 414.350 to 414.415, including the type of
software programs to be used by the pharmacist for prospective
drug use review and the provisions of the contractual agreement
between the state and any entity involved in the retrospective
drug use review program.
    { - (3) - }   { + (c) + } Development of and application of
the criteria and standards to be used in retrospective and
prospective drug utilization review in a manner that insures that
such criteria and standards are based on the compendia, relevant
guidelines obtained from professional groups through
consensus-driven processes, the experience of practitioners with
expertise in drug therapy, data and experience obtained from drug
utilization review program operations. The board shall have an
open professional consensus process for establishing and revising
criteria and standards.  Criteria and standards shall be
available to the public. In developing recommendations for
criteria and standards, the board shall establish an explicit
ongoing process for soliciting and considering input from
interested parties. The board shall make timely revisions to the
criteria and standards based upon this input in addition to
revisions based upon scheduled review of the criteria and
standards. Further, the drug utilization review standards shall
reflect the local practices of prescribers in order to monitor:
    { - (a) - }   { + (A) + } Therapeutic appropriateness.
    { - (b) - }   { + (B) + } Overutilization or
underutilization.
    { - (c) - }   { + (C) + } Therapeutic duplication.
    { - (d) - }   { + (D) + } Drug-disease contraindications.
    { - (e) - }   { + (E) + } Drug-drug interactions.
    { - (f) - }   { + (F) + } Incorrect drug dosage or drug
treatment duration.
 
 
Enrolled House Bill 2558 (HB 2558-INTRO)                   Page 1
 
 
 
    { - (g) - }   { + (G) + } Clinical abuse or misuse.
    { - (h) - }   { + (H) + } Drug allergies.
    { - (4) - }   { + (d) + } Development, selection and
application of and assessment for interventions for medical
assistance program prescribers, dispensers and patients that are
educational and not punitive in nature.
   { +  (2) In reviewing retrospective and prospective drug use,
the board may consider only drugs that have received final
approval from the federal Food and Drug Administration. + }
  SECTION 2. ORS 414.370 is amended to read:
  414.370. In appropriate instances, interventions developed
under ORS 414.360   { - (4) - }   { + (1)(d) + } may include the
following:
  (1) Information disseminated to prescribers and pharmacists to
insure that they are aware of the duties and powers of the Drug
Use Review Board.
  (2) Written, oral or electronic reminders of recipient-specific
or drug-specific information that are designed to insure
recipient, prescriber and pharmacist confidentiality, and
suggested changes in the prescribing or dispensing practices
designed to improve the quality of care.
  (3) Face-to-face discussions between experts in drug therapy
and the prescriber or pharmacist who has been targeted for
educational intervention.
  (4) Intensified reviews or monitoring of selected prescribers
or pharmacists.
  (5) Educational outreach through the retrospective program
focusing on improvement of prescribing and dispensing practices.
  (6) The timely evaluation of interventions to determine if the
interventions have improved the quality of care.
  (7) The review of case profiles before the conducting of an
intervention.
                         ----------
 
 
Passed by House March 25, 2003
 
 
      ...........................................................
                                             Chief Clerk of House
 
      ...........................................................
                                                 Speaker of House
 
Passed by Senate April 18, 2003
 
 
      ...........................................................
                                              President of Senate
 
 
 
 
 
 
 
 
 
 
 
 
 
Enrolled House Bill 2558 (HB 2558-INTRO)                   Page 2
 
 
 
 
 
Received by Governor:
 
......M.,............., 2003
 
Approved:
 
......M.,............., 2003
 
 
      ...........................................................
                                                         Governor
 
Filed in Office of Secretary of State:
 
......M.,............., 2003
 
 
      ...........................................................
                                               Secretary of State
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Enrolled House Bill 2558 (HB 2558-INTRO)                   Page 3